Umlaut.bio GmbH
- Biotech or pharma, therapeutic R&D
Umlaut.bio is pioneering small-molecule therapeutics that target tRNA modifications – a first-in-biology approach with broad potential in cancer and autoimmune diseases.
By disrupting key steps in tRNA modification synthesis, Umlaut.bio addresses upstream drivers of pathological signaling that cannot be controlled by conventional therapies.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}